Statements (135)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:DNA
|
| gptkbp:associated_with |
gptkb:chronic_myeloid_leukemia
gptkb:cancer_treatment gptkb:Oncology gptkb:BCR-ABL_fusion_protein clinical trials drug development genetic testing molecular diagnostics personalized medicine therapeutic interventions cancer research genetic research genetic mutations therapeutic strategies genetic predisposition targeted therapy molecular genetics biological pathways clinical outcomes therapeutic efficacy molecular biology research targeted cancer therapies cancer susceptibility poor prognosis clinical implications therapeutic resistance cancer genetics drug resistance treatment options clinical management molecular mechanisms oncogenic signaling molecular profiling cancer biomarkers hematological malignancies therapeutic monitoring cancer prognosis cancer treatment resistance genomic alterations clinical trials for leukemia molecular targets CML treatment resistance biomarker for therapy cancer pathogenesis leukemia progression molecular diagnostics for leukemia |
| gptkbp:clinical_trial |
diagnostic marker
|
| gptkbp:code |
gptkb:ABL1_protein
tyrosine kinase |
| gptkbp:discovered_by |
gptkb:1980s
gptkb:Dr._Janet_Rowley |
| gptkbp:diseases |
gptkb:Oncology
myeloproliferative neoplasms myeloproliferative disorders |
| gptkbp:function |
cell signaling
|
| gptkbp:genetic_studies |
chromosomal instability
tumorigenesis deletion point mutation increased cell proliferation altered signaling pathways various cancers altered protein function cellular transformation resistance to apoptosis enhanced oncogenic activity increased kinase activity translocation increased tyrosine kinase activity |
| gptkbp:has_variants |
gptkb:ABL1_fusion_proteins
|
| https://www.w3.org/2000/01/rdf-schema#label |
ABL1 gene
|
| gptkbp:initiated_by |
apoptosis
|
| gptkbp:interacts_with |
other signaling proteins
|
| gptkbp:involved_in |
gptkb:Philadelphia_chromosome
cell cycle regulation cell differentiation cell proliferation |
| gptkbp:is_associated_with |
inflammation
disease progression genetic predisposition poor prognosis therapeutic resistance treatment resistance |
| gptkbp:is_essential_for |
normal hematopoiesis
|
| gptkbp:is_expressed_in |
gptkb:Cell
gptkb:embryonic_development various tissues cancer cells various cancers hematopoietic cells |
| gptkbp:is_involved_in |
cancer therapy
immune response signal transduction DNA repair mechanisms tumorigenesis cell survival tumor microenvironment cell adhesion cell migration cellular signaling pathways tumor progression |
| gptkbp:is_linked_to |
treatment efficacy
chromosomal abnormalities clinical outcomes therapeutic outcomes metastasis drug resistance |
| gptkbp:is_located_in |
chromosome 9
|
| gptkbp:is_part_of |
signal transduction pathways
cancer research |
| gptkbp:is_recognized_as |
gptkb:Philadelphia_chromosome
|
| gptkbp:is_regulated_by |
transcription factors
|
| gptkbp:is_studied_for |
gptkb:gene_therapy
personalized medicine therapeutic interventions clinical applications biomarker development |
| gptkbp:is_studied_in |
clinical trials
|
| gptkbp:is_targeted_at |
targeted therapies
monoclonal antibodies small molecule inhibitors combination therapies novel agents |
| gptkbp:located_in |
human chromosome 9
|
| gptkbp:part_of |
gptkb:BCR-ABL_fusion_gene
|
| gptkbp:regulates |
cell cycle progression
|
| gptkbp:research_focus |
cancer therapy
cancer biology |
| gptkbp:role |
signal transduction
|
| gptkbp:seed_dispersal |
gptkb:Oni
|
| gptkbp:targets |
gptkb:imatinib
|
| gptkbp:therapeutic_target_for |
gptkb:imatinib
|
| gptkbp:bfsParent |
gptkb:BCR_gene
|
| gptkbp:bfsLayer |
7
|